Rescheduling cannabis: Regulatory and tax perspectives on the road ahead
Receive viewpoints, business intelligence, and other resources on cannabis topics relevant to your business and role. Subscribe
Earlier this month, Bloomberg reported that the Department of Health and Human Services (HHS) has recommended that the Drug Enforcement Administration (DEA) move cannabis from Schedule I of the Controlled Substances Act to Schedule III.
Such a move would have vast implications for the industry, from opening the door for expanded markets to greatly loosening the tax restrictions currently imposed by IRC Section 280E. But, the road to that point is far from certain.
CohnReznick’s Michael Harlow sat down with two experienced industry professionals to explore their perspectives on the various tax and regulatory questions, implications, and milestones we may see along the road ahead.
Note: The perspectives presented by the speakers do not necessarily reflect the perspective of CohnReznick.
Regulatory Perspectives: David Feldman, Feldman Legal Advisors
Tax Perspectives: Nate Pollock, SouthBank Legal
Nate Pollock is a partner at SouthBank Legal, where he launched a tax controversy practice. Previously, he spent 18 years at the Department of Justice, where his experience included briefing and arguing Section 280E cases on appeal.
Cannabis Quarterly Insights, Q3 2023: Business Strategies and Trends
Subject matter expertise
Michael D. Harlow
CPA, Partner, Managing Partner – Cannabis Industry
Let’s start a conversation about your company’s strategic goals and vision for the future.
Please fill all required fields*
Please verify your information and check to see if all require fields have been filled in.